These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
220 related articles for article (PubMed ID: 20696962)
1. Gout, allopurinol use, and heart failure outcomes. Thanassoulis G; Brophy JM; Richard H; Pilote L Arch Intern Med; 2010 Aug; 170(15):1358-64. PubMed ID: 20696962 [TBL] [Abstract][Full Text] [Related]
2. Factors associated with recurrent hospital admissions for gout: a case-control study. Hutton I; Gamble G; Gow P; Dalbeth N J Clin Rheumatol; 2009 Sep; 15(6):271-4. PubMed ID: 19734730 [TBL] [Abstract][Full Text] [Related]
3. Uric acid, allopurinol therapy, and mortality in patients with acute heart failure--results of the Acute HEart FAilure Database registry. Málek F; Ošťádal P; Pařenica J; Jarkovský J; Vítovec J; Widimský P; Linhart A; Fedorco M; Coufal Z; Miklík R; Krűger A; Vondraková D; Špinar J J Crit Care; 2012 Dec; 27(6):737.e11-24. PubMed ID: 22699032 [TBL] [Abstract][Full Text] [Related]
4. Anemia and outcomes in patients with heart failure: a study from the National Heart Care Project. Kosiborod M; Curtis JP; Wang Y; Smith GL; Masoudi FA; Foody JM; Havranek EP; Krumholz HM Arch Intern Med; 2005 Oct; 165(19):2237-44. PubMed ID: 16246989 [TBL] [Abstract][Full Text] [Related]
5. Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout. Dalbeth N; Kumar S; Stamp L; Gow P J Rheumatol; 2006 Aug; 33(8):1646-50. PubMed ID: 16783857 [TBL] [Abstract][Full Text] [Related]
6. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Schumacher HR; Becker MA; Wortmann RL; Macdonald PA; Hunt B; Streit J; Lademacher C; Joseph-Ridge N Arthritis Rheum; 2008 Nov; 59(11):1540-8. PubMed ID: 18975369 [TBL] [Abstract][Full Text] [Related]
7. Retrospective claims database analysis to determine relationship between renin-angiotensin system agents, rehospitalization, and health care costs in patients with heart failure or myocardial infarction. Sun SX; Ye X; Lee KY; Dupclay L; Plauschinat C Clin Ther; 2008; 30 Pt 2():2217-27. PubMed ID: 19281916 [TBL] [Abstract][Full Text] [Related]
8. Serum urate levels and gout flares: analysis from managed care data. Sarawate CA; Patel PA; Schumacher HR; Yang W; Brewer KK; Bakst AW J Clin Rheumatol; 2006 Apr; 12(2):61-5. PubMed ID: 16601538 [TBL] [Abstract][Full Text] [Related]
9. Outcomes in heart failure patients after major noncardiac surgery. Hernandez AF; Whellan DJ; Stroud S; Sun JL; O'Connor CM; Jollis JG J Am Coll Cardiol; 2004 Oct; 44(7):1446-53. PubMed ID: 15464326 [TBL] [Abstract][Full Text] [Related]
10. Relationship of a quality measure composite to clinical outcomes for patients with heart failure. Chung ES; Lin Guo ; Casey DE; Bartone C; Menon S; Saghir S; Mital A; Kereiakes DJ Am J Med Qual; 2008; 23(3):168-75. PubMed ID: 18539977 [TBL] [Abstract][Full Text] [Related]
11. Opportunities for improving medication use and monitoring in gout. Singh JA; Hodges JS; Asch SM Ann Rheum Dis; 2009 Aug; 68(8):1265-70. PubMed ID: 18701554 [TBL] [Abstract][Full Text] [Related]
12. Compliance with allopurinol therapy among managed care enrollees with gout: a retrospective analysis of administrative claims. Riedel AA; Nelson M; Joseph-Ridge N; Wallace K; MacDonald P; Becker M J Rheumatol; 2004 Aug; 31(8):1575-81. PubMed ID: 15290738 [TBL] [Abstract][Full Text] [Related]
13. beta-Blocker use in long-term dialysis patients: association with hospitalized heart failure and mortality. Abbott KC; Trespalacios FC; Agodoa LY; Taylor AJ; Bakris GL Arch Intern Med; 2004 Dec 13-27; 164(22):2465-71. PubMed ID: 15596637 [TBL] [Abstract][Full Text] [Related]
14. A new programme of multidisciplinary care for patients with heart failure in Poznań: one-year follow-up. Wierzchowiecki M; Poprawski K; Nowicka A; Kandziora M; Piatkowska A; Jankowiak M; Michałowicz B; Stawski W; Dziamska M; Kaszuba D; Szymanowska K; Michalski M Kardiol Pol; 2006 Oct; 64(10):1063-70; discussion 1071-2. PubMed ID: 17089238 [TBL] [Abstract][Full Text] [Related]
15. Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout. Becker MA; Schumacher HR; MacDonald PA; Lloyd E; Lademacher C J Rheumatol; 2009 Jun; 36(6):1273-82. PubMed ID: 19286847 [TBL] [Abstract][Full Text] [Related]
16. Characteristics and outcomes of very elderly patients after first hospitalization for heart failure. Shah RU; Tsai V; Klein L; Heidenreich PA Circ Heart Fail; 2011 May; 4(3):301-7. PubMed ID: 21467294 [TBL] [Abstract][Full Text] [Related]
17. Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol. Stamp LK; Taylor WJ; Jones PB; Dockerty JL; Drake J; Frampton C; Dalbeth N Arthritis Rheum; 2012 Aug; 64(8):2529-36. PubMed ID: 22488501 [TBL] [Abstract][Full Text] [Related]
18. Impact of care at a multidisciplinary congestive heart failure clinic: a randomized trial. Ducharme A; Doyon O; White M; Rouleau JL; Brophy JM CMAJ; 2005 Jul; 173(1):40-5. PubMed ID: 15997043 [TBL] [Abstract][Full Text] [Related]
19. Impact of noncompliance with urate-lowering drug on serum urate and gout-related healthcare costs: administrative claims analysis. Halpern R; Mody RR; Fuldeore MJ; Patel PA; Mikuls TR Curr Med Res Opin; 2009 Jul; 25(7):1711-9. PubMed ID: 19485724 [TBL] [Abstract][Full Text] [Related]
20. Effect of moderate or intensive disease management program on outcome in patients with heart failure: Coordinating Study Evaluating Outcomes of Advising and Counseling in Heart Failure (COACH). Jaarsma T; van der Wal MH; Lesman-Leegte I; Luttik ML; Hogenhuis J; Veeger NJ; Sanderman R; Hoes AW; van Gilst WH; Lok DJ; Dunselman PH; Tijssen JG; Hillege HL; van Veldhuisen DJ; Arch Intern Med; 2008 Feb; 168(3):316-24. PubMed ID: 18268174 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]